Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials

被引：0
|
作者：
Run-Cong Nie
Xue-Bin Zou
Shu-Qiang Yuan
Ying-Bo Chen
Shi Chen
Yong-Ming Chen
Guo-Ming Chen
Xiao-Jiang Chen
Tian-Qi Luo
Shu-Man Li
Jin-Ling Duan
Yun Wang
Yuan-Fang Li
机构：
[1] Sun Yat-sen University Cancer Center,Department of Gastric Surgery
[2] State Key Laboratory of Oncology in South China,Department of Ultrasound, Sun Yat
[3] Collaborative Innovation Center for Cancer Medicine,sen University Cancer Center, State Key Laboratory of Oncology in South China
[4] Collaborative Innovation Center for Cancer Medicine,Department of Gastric Surgery, The 6th Affiliated Hospital
[5] Sun Yat-sen University,Department of Experimental Research (Cancer Institute)
[6] Sun Yat-sen University Cancer Center,Department of Hematologic Oncology, Sun Yat
[7] State Key Laboratory of Oncology in South China,sen University Cancer Center, State Key Laboratory of Oncology in South China
[8] Collaborative Innovation Center for Cancer Medicine,undefined
[9] Collaborative Innovation Center for Cancer Medicine,undefined
来源：
BMC Cancer | / 20卷
关键词：
Pancreatic cancer; Disease-free survival; Overall survival; Surrogate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] PROGRESSION-FREE SURVIVAL IS A ROBUST SURROGATE ENDPOINT OF OVERALL SURVIVAL IN IMMUNOTHERAPY TRIALS OF HEPATOCELLULAR CARCINOMA
    Cabibbo, Giuseppe
    Celsa, Ciro
    Enea, Marco
    Battaglia, Salvatore
    Rizzo, Giacomo
    Busacca, Anita
    Matranga, Domenica
    Attanasio, Massimo
    Reig, Maria
    Craxi, Antonio
    Camma, Calogero
    HEPATOLOGY, 2020, 72 : 649A - 649A
  • [42] Progression-free survival is a robust surrogate endpoint of overall survival in immunotherapy trials of hepatocellular carcinoma
    Celsa, C.
    Cabibbo, G.
    Enea, M.
    Battaglia, S.
    Rizzo, G. E. M.
    Busacca, A.
    Matranga, D.
    Attanasio, M.
    Reig, M.
    Craxi, A.
    Camma, C.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 : S35 - S35
  • [43] Disease-Free Survival is a Promising Surrogate for Overall Survival in Colorectal Cancer Studies
    Morris, Jeffrey S.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (01): : 5 - 6
  • [44] Progression-free survival as a surrogate endpoint for hazard ratio and median overall survival in glioblastoma: A literature-based meta-analysis from 91 trials
    Han, K.
    Ren, M.
    Wick, W.
    Jin, J.
    Abrey, L.
    Das, A.
    Reardon, D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S775 - S776
  • [45] Influence of resection margins and treatment on survival in patients with pancreatic cancer -: Meta-analysis of randomized controlled trials
    Butturini, Giovanni
    Stocken, Deborah D.
    Wente, Moritz N.
    Jeekel, Hans
    Klinkenbijl, Johaness H. G.
    Bakkevold, Kare E.
    Takada, Tadahiro
    Amano, Hirano
    Dervenis, Christos
    Bassi, Claudio
    Buechler, Markus W.
    Neoptolemos, John P.
    ARCHIVES OF SURGERY, 2008, 143 (01) : 75 - 83
  • [46] Metformin and survival of women with breast cancer: A meta-analysis of randomized controlled trials
    Wang, Qiandan
    Ma, Xiufen
    Long, Jianping
    Du, Xiaoyan
    Pan, Bin
    Mao, Hongyan
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (03) : 263 - 269
  • [47] Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials
    Petrelli, Fausto
    Borgonovo, Karen
    Cabiddu, Mary
    Ghilardi, Mara
    Lonati, Veronica
    Barni, Sandro
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (01) : 39 - 48
  • [48] The validity of progression-free survival (PFS) 2 as a surrogate endpoint for overall survival (OS) in randomized controlled trials (RCTs) of advanced solid tumors.
    Woodford, Rachel
    Zhou, Deborah
    Kok, Peey-Sei
    Lord, Sally
    Marschner, Ian
    Friedlander, Michael
    Lee, Chee Khoon
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Adjuvant LH-RH agonists for premenopausal early breast cancer: A meta-analysis of randomized clinical trials (RCTs) exploring the magnitude of the disease-free and overall survival (DFS/OS) benefit
    Carlini, P.
    Bria, E.
    Cuppone, F.
    Papaldo, P.
    Nistico, C.
    Fabi, A.
    Ruggeri, E. M.
    Terzoli, E.
    Cognetti, F.
    Giannarelli, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] Disease-free survival as the endpoint in multimodal rectal cancer trials: have we got this right?
    Fokas, Emmanouil
    Roedel, Claus
    Smith, J. Joshua
    Garcia-Aguilar, Julio
    Buyse, Marc
    Glynne-Jones, Robert
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (11): : 962 - 964
12345